The US Patent Office has allowed a patent for Bioretec’s RemeOs magnesium alloy composition and will grant and publish it upon company confirmation.

The patent encompasses the use of the RemeOs magnesium-calcium-zinc alloy in the manufacturing of orthopaedic implants or parts thereof for all patient demographics.

This alloy is a crucial component of Bioretec's trauma screws and is expected to be incorporated into future product offerings.

The company is also advancing its efforts to secure international protection for the RemeOs alloy by initiating a PCT [Patent Cooperation Treaty] application that would extend its patent coverage beyond the US.

Bioretec CEO Timo Lehtonen said: “The allowance of this patent for RemeOs biodegradable metal composition in the US, which is our main target market, is an integral part of our IPR strategy and protection of RemeOs technology.”

The company is pioneering the development of the RemeOs product line, which makes use of magnesium alloy and hybrid composite to introduce a new era of biodegradable materials aimed at enhancing surgical outcomes.

These RemeOs implants are designed to be gradually absorbed and replaced by bone, eliminating the necessity for removal surgery and expediting fracture healing.

The company’s first RemeOs product received market authorisation in the US in March last year. The CE mark in Europe is anticipated by the second quarter of 2024.

In 2022, Bioretec submitted an application seeking a CE mark for its bioresorbable RemeOs trauma screw to commercialise in the EU. The magnesium alloy trauma screw is part of the company’s new RemeOs product family.